Cross-sectional association between markers of inflammation and serum sex steroid levels in the postmenopausal estrogen/progestin interventions trial

被引:36
作者
Crandall, C
Palla, S
Reboussin, B
Hu, P
Barrett-Connor, E
Reuben, D
Greendale, G
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90024 USA
[2] Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA USA
[4] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA USA
关键词
D O I
10.1089/jwh.2006.15.14
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Standard risk factors do not adequately capture cardiovascular risk in postmenopausal women. We sought to determine the associations between levels of sex steroids and levels of inflammatory markers in postmenopausal women. Methods: We analyzed baseline data from a subset of postmenopausal women aged 45-64 years who had stored samples during a randomized controlled trial. We measured levels of C-reactive protein (CRP), interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9), soluble intercellular adhesion molecule (sICAM), and circulating sex steroids. Multiple linear regression models were created with each of the following hormone levels as the primary exposure variable: estrone, total estradiol, bioavailable estradiol, total testosterone, bioavailable testosterone, progesterone, and sex hormone-binding globulin (SHBG). Sociodemographic and lifestyle covariates were derived from standardized self-report questionnaires and direct measurement (weight, height). Results: Mean age of the 623 women was 56 years. After adjustment for age, body mass index (BMI), physical activity, alcohol consumption, and smoking, the bioavailable testosterone level (p = 0.03) was positively and the SHBG level (p = 0.001) was negatively associated with the logCRP level. The increment in CRP level between the highest and lowest quartile of bioavailable testosterone was 1.28 mu g/mL. The increment in CRP level between the lowest and highest quartile of SHBG was 2.62 mu g/mL. Compared with SHBG or bioavailable testosterone as predictors of logCRP in separate regression models, when both SHBG and bioavailable testosterone were included in the same multivariate linear regression model, only SHBG remained a statistically significant predictor of logCRP. Progesterone level was positively associated with the logMMP-9 level (p < 0.001); no other sex steroid level was associated with the logMMP-9 level. In multiply adjusted models, no association was found between levels of any sex steroid and IL-6 or sICAM level.
引用
收藏
页码:14 / 23
页数:10
相关论文
共 40 条
  • [1] SIMPLE METHOD FOR ASSAY OF 8 STEROIDS IN SMALL VOLUMES OF PLASMA
    ANDERSON, DC
    HOPPER, BR
    LASLEY, BL
    YEN, SSC
    [J]. STEROIDS, 1976, 28 (02) : 179 - 196
  • [2] Anderson Robert N, 2003, Natl Vital Stat Rep, V52, P1
  • [3] Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women
    Barinas-Mitchell, E
    Cushman, M
    Meilahn, EN
    Tracy, RP
    Kuller, LH
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2001, 153 (11) : 1094 - 1101
  • [4] Adhesion molecules and atherosclerosis
    Blankenberg, S
    Barbaux, S
    Tiret, L
    [J]. ATHEROSCLEROSIS, 2003, 170 (02) : 191 - 203
  • [5] A DATA-BASED APPROACH TO DIET QUESTIONNAIRE DESIGN AND TESTING
    BLOCK, G
    HARTMAN, AM
    DRESSER, CM
    CARROLL, MD
    GANNON, J
    GARDNER, L
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1986, 124 (03) : 453 - 469
  • [6] A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition
    Burger, HG
    Dudley, EC
    Cui, JS
    Dennerstein, L
    Hopper, JL
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (08) : 2832 - 2838
  • [7] Effects of hormone therapy on bone mineral density - Results from the postmenopausal estrogen/progestin interventions (PEPI) trial
    Bush, TL
    Wells, HB
    James, MK
    BarrettConnor, E
    Marcus, R
    Greendale, G
    Hunsberger, S
    McGowan, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (17): : 1389 - 1396
  • [8] Effect of postmenopausal hormones on inflammation-sensitive proteins - The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
    Cushman, M
    Legault, C
    Barrett-Connor, E
    Stefanick, ML
    Kessler, C
    Judd, HL
    Sakkinen, PA
    Tracy, RP
    [J]. CIRCULATION, 1999, 100 (07) : 717 - 722
  • [9] Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis
    Dunaif, A
    [J]. ENDOCRINE REVIEWS, 1997, 18 (06) : 774 - 800
  • [10] Medical progress: Polycystic ovary syndrome
    Ehrmann, DA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (12) : 1223 - 1236